{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:02:14Z","timestamp":1787317334000,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antipsychotics improve the positive symptoms of schizophrenia. However, little is known about the extent of antidepressive effects of antipsychotics and their correlation with effects on other symptom domains in schizophrenia. The aim was to investigate whether antidepressive effects of antipsychotics have a significant correlation with the effects on specific symptom domains of schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Electronic databases were searched to identify eligible studies that reported antidepressive effects of antipsychotics for the treatment of adult patients with schizophrenia in double-blind, randomized placebo-controlled trials (RCTs). Mean change from baseline in depressive symptoms was meta-analyzed, and the correlation with the effects on other symptom domains was examined through meta-regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five RCTs (13\u2009890 patients) were included in this meta-analysis. Overall, antipsychotics showed greater efficacy than placebo in reducing depressive symptoms, with small to medium effect sizes (standardized mean difference\u2009=\u2009\u22120.27, 95% confidence interval \u22120.32 to \u22120.22, P\u2009&amp;lt;\u2009.001). All the antipsychotics, except for chlorpromazine, haloperidol, and ziprasidone, were associated with significantly greater decreases in depressive symptoms compared with placebo (standardized mean difference\u2009=\u2009\u22120.19 to \u22120.40). A higher antidepressive effect was significantly correlated with a higher improvement in Positive and Negative Syndrome Scale\/Brief Psychiatric Rating Scale total, positive, and negative, and Positive and Negative Syndrome Scale-general psychopathology symptoms (\u03b2\u2009=\u2009.618, P\u2009&amp;lt;\u2009.001; \u03b2\u2009=\u2009.476, P\u2009&amp;lt;\u2009.001; \u03b2\u2009=\u2009.689, P\u2009&amp;lt;\u2009.001; \u03b2\u2009=\u2009.603, P\u2009&amp;lt;\u2009.001, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Second-generation antipsychotics (except for ziprasidone) were associated with small to medium effects sizes on improvement in depressive symptoms among adult patients with schizophrenia. The antidepressive effect of antipsychotics was significantly correlated with improvement in other symptom domains, with the highest correlation observed for improvement in negative symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42019133015<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa082","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T08:10:23Z","timestamp":1603959023000},"page":"200-215","source":"Crossref","is-referenced-by-count":15,"title":["Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials"],"prefix":"10.1093","volume":"24","author":[{"given":"Itaru","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirooki","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Hagi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2021031717301933500_CIT0001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"S22","author":"Addington","year":"1993","journal-title":"Br J Psychiatry"},{"key":"2021031717301933500_CIT0002","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1192\/S0007125000297729","article-title":"Depression in people with first episode schizophrenia","volume":"172","author":"Addington","year":"1998","journal-title":"Br J Psychiatry, Supplement"},{"key":"2021031717301933500_CIT0003","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1982.04290070025006","article-title":"Negative v positive schizophrenia. Definition and validation","volume":"39","author":"Andreasen","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"2021031717301933500_CIT0004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0010-440X(92)90045-R","article-title":"Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia","volume":"33","author":"Bermanzohn","year":"1992","journal-title":"Compr Psychiatry"},{"key":"2021031717301933500_CIT0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1034\/j.1600-0447.2000.90063.x","article-title":"Prevalence and background factors of depression in first admitted schizophrenic patients","volume":"101","author":"Bottlender","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"2021031717301933500_CIT0006","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/schbul\/sbn135","article-title":"Psychiatric comorbidities and schizophrenia","volume":"35","author":"Buckley","year":"2009","journal-title":"Schizophr Bull"},{"key":"2021031717301933500_CIT0007","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-2007-999063","article-title":"[Depression in the early course of schizophrenia]","volume":"62","author":"Bustamante","year":"1994","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2021031717301933500_CIT0008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/schbul\/11.3.440","article-title":"Treatment of negative symptoms","volume":"11","author":"Carpenter","year":"1985","journal-title":"Schizophr Bull"},{"key":"2021031717301933500_CIT0009","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","article-title":"The burden of depressive symptoms in the long-term treatment of patients with schizophrenia","volume":"90","author":"Conley","year":"2007","journal-title":"Schizophr Res"},{"key":"2021031717301933500_CIT0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"2021031717301933500_CIT0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2021031717301933500_CIT0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"2021031717301933500_CIT0013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2021031717301933500_CIT0014","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","article-title":"Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies","volume":"72","author":"Furukawa","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2021031717301933500_CIT0015","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr Bull"},{"key":"2021031717301933500_CIT0016","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2021031717301933500_CIT0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/acps.12854","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"2021031717301933500_CIT0018","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4088\/JCP.13m08675","article-title":"National trends in second-generation antipsychotic augmentation for nonpsychotic depression","volume":"75","author":"Gerhard","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2021031717301933500_CIT0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archgenpsychiatry.2011.129","article-title":"Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia","volume":"69","author":"Grant","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"2021031717301933500_CIT0020","volume-title":"ECDEU assessment manual for psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"2021031717301933500_CIT0021","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021031717301933500_CIT0022","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2021031717301933500_CIT0023","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2021031717301933500_CIT0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1192\/bjp.140.4.421","article-title":"Depression \u201crevealed\u201d in schizophrenia","volume":"140","author":"Hirsch","year":"1982","journal-title":"Br J Psychiatry"},{"key":"2021031717301933500_CIT0025","first-page":"77","article-title":"Clozapine: antipsychotic activity in treatment-resistant schizophrenics","volume":"1","author":"Honigfeld","year":"1984","journal-title":"Adv Ther"},{"key":"2021031717301933500_CIT0026","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"2021031717301933500_CIT0027","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00406-006-0683-1","article-title":"Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders","volume":"257","author":"J\u00e4ger","year":"2007","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2021031717301933500_CIT0028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2021031717301933500_CIT0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology"},{"key":"2021031717301933500_CIT0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","article-title":"The global costs of schizophrenia","volume":"30","author":"Knapp","year":"2004","journal-title":"Schizophr Bull"},{"key":"2021031717301933500_CIT0031","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1176\/ajp.150.11.1643","article-title":"Depression in first-episode schizophrenia","volume":"150","author":"Koreen","year":"1993","journal-title":"Am J Psychiatry"},{"key":"2021031717301933500_CIT0032","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/acps.12873","article-title":"The relationship between negative symptoms and depression in schizophrenia: a systematic review","volume":"137","author":"Krynicki","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"2021031717301933500_CIT0033","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2011.10.014","article-title":"A systematic review of instruments to measure depressive symptoms in patients with schizophrenia","volume":"140","author":"Lako","year":"2012","journal-title":"J Affect Disord"},{"key":"2021031717301933500_CIT0034","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2021031717301933500_CIT0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.psychres.2018.04.016","article-title":"Depressive symptoms in Chinese male inpatients with schizophrenia: prevalence and clinical correlates","volume":"264","author":"Li","year":"2018","journal-title":"Psychiatry Res"},{"key":"2021031717301933500_CIT0036","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0010-440X(91)90032-8","article-title":"Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms","volume":"32","author":"Lindenmayer","year":"1991","journal-title":"Compr Psychiatry"},{"key":"2021031717301933500_CIT0037","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.comppsych.2011.03.009","article-title":"Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia","volume":"53","author":"Majadas","year":"2012","journal-title":"Compr Psychiatry"},{"key":"2021031717301933500_CIT0038","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archpsyc.1982.04290020051010","article-title":"Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics","volume":"39","author":"Mandel","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"2021031717301933500_CIT0039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archpsyc.1976.01770020065011","article-title":"Postpsychotic depression in schizophrenia","volume":"33","author":"McGlashan","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"2021031717301933500_CIT0040","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2021031717301933500_CIT0041","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2021031717301933500_CIT0042","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1192\/apt.6.3.169","article-title":"The symptom of depression in schizophrenia and its management","volume":"6","author":"Mulholland","year":"2000","journal-title":"Adv Psychiatr Treat"},{"key":"2021031717301933500_CIT0043","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"2021031717301933500_CIT0044","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4088\/JCP.v69n0114","article-title":"Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study","volume":"69","author":"Perkins","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2021031717301933500_CIT0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1600-0447.2003.00132.x","article-title":"Depression and subjective quality of life in chronic phase schizophrenic patients","volume":"108","author":"Reine","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"2021031717301933500_CIT0046","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jad.2013.01.018","article-title":"The subjective experience and phenomenology of depression following first episode psychosis: a qualitative study using photo-elicitation","volume":"149","author":"Sandhu","year":"2013","journal-title":"J Affect Disord"},{"key":"2021031717301933500_CIT0047","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/oxfordjournals.schbul.a033362","article-title":"Depression during the longitudinal course of schizophrenia","volume":"25","author":"Sands","year":"1999","journal-title":"Schizophr Bull"},{"key":"2021031717301933500_CIT0048","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.psychres.2004.07.007","article-title":"Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression","volume":"129","author":"Sim","year":"2004","journal-title":"Psychiatry Res"},{"key":"2021031717301933500_CIT0049","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","article-title":"Depression in schizophrenia: perspective in the era of \u201catypical\u201d antipsychotic agents","volume":"157","author":"Siris","year":"2000","journal-title":"Am J Psychiatry"},{"key":"2021031717301933500_CIT0050","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1176\/ajp.145.12.1532","article-title":"Postpsychotic depression and negative symptoms: an investigation of syndromal overlap","volume":"145","author":"Siris","year":"1988","journal-title":"Am J Psychiatry"},{"key":"2021031717301933500_CIT0051","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/9780470987353.ch9","article-title":"Depression and schizophrenia","volume-title":"Schizophrenia","author":"Siris","year":"2003","edition":"2nd ed."},{"key":"2021031717301933500_CIT0052","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archpsyc.1978.01770330075006","article-title":"\u201cAkinetic depression\u201d in schizophrenia","volume":"35","author":"Van Putten","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"2021031717301933500_CIT0053","doi-asserted-by":"crossref","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"25","author":"Zhou","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021031717301933500_CIT0054","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa082\/34564933\/pyaa082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/3\/200\/36626536\/pyaa082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/3\/200\/36626536\/pyaa082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T13:32:20Z","timestamp":1615987940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/24\/3\/200\/5957072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2021,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa082","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,5]]}}}